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Essential isoprenoid compounds are synthesized using the 2-C-methyl-n-erythritol 4-phosphate (MEP) 
pathway in many gram-negative bacteria, some gram-positive bacteria, some apicomplexan parasites, and 
plant chloroplasts. The alternative mevalonate pathway is found in archaea and eukaryotes, including cytosolic 
biosynthesis in plants. The existence of orthogonal essential pathways in eukaryotes and bacteria makes the 
MEP pathway an attractive target for the development of antimicrobial agents. A system is described for 
identifying mutations in the MEP pathway of Salmonella enterica serovar Tvphimurium. Using this system, 
point mutations induced by diethyl sulfate were found in the all genes of the essential MEP pathway and also 
in genes involved in uptake of methylerythritol. Curiously, none of the MEP pathway genes could be identified 
in the same parent strain by transposon mutagenesis, despite extensive searches. The results complement the 
biochemical and bioinformatic approaches to the elucidation of the genes involved in the MEP pathway and 
also identify key residues for activity in the enzymes of the pathway.
It was recently discovered that bacteria synthesize isopre- 
noids by a pathway that differs from that found in eukaryotes. 
In bacteria, pyruvate and glyceraldehyde 3-phosphate are con­
verted, through the 2-C-methyl-n-erythritol phosphate (MEP) 
pathway, to isopentenyl diphosphate (IPP) and dimethylallyl 
diphosphate (DMAPP). This has focused recent research on 
the elucidation of the biosynthetic steps and genes encoding 
the catalytic enzymes in bacteria. To date, all synthetic steps 
of the MEP pathway and the genes encoding the biosynthetic 
enzymes have been identified. Isoprenoid biosynthesis begins 
with the condensation of pyruvate and glyceraldehyde 3-phos­
phate by 1-deoxy-n-xylulose 5-phosphate (DXP) synthase, en­
coded by dxs (26). Next, in the first committed step of the 
pathway, DXP reductoisomerase, encoded by dxr, converts 
DXP to MEP (16, 32). In the following three steps, a cytidyl 
monophosphate moiety is attached to the phosphate of MEP; 
the resulting diphosphodiester is phosphorylated at the C-2 
hydroxyl in the methylerythritol moiety and then cyclized to 
form an eight-membered cyclic diphosphate diester, and these 
steps are catalyzed by the proteins encoded by ispD (25), ispE 
(18), and ispF (11), respectively. The enzyme encoded by ispG, 
I-hydroxy-2-methyl-2-(E)-butenol 4-diphosphate (HDMAPP) 
synthase, catalyzes the ring opening and reduction of 2-C- 
methyl-n-erythritol-2,4-cyclodiphosphate to yield HDMAPP 
(10). Finally, HDMAPP is converted to a mixture of IPP and 
DMAPP by HDMAPP reductase encoded by ispH (1).
Mutants blocked in the MEP pathway of Salmonella spp. or 
Escherichia coli are expected to be lethal, since these organisms 
are unable to utilize exogenously supplied IPP, DMAPP, or 
their corresponding alcohols. To allow viability of such mu­
tants, genes of the alternative mevalonate pathway were intro­
duced into bacteria, either on plasmids or in the chromosome 
(2, 5, 9, 15, 24). Strains containing the genes of the mevalonate 
pathway can synthesize isoprenoids using the eukaryotic
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pathway when mevalonate is provided. This allows identifi­
cation of mutants blocked in the alternative bacterial path­
way by their requirement for mevalonate. An approach sim­
ilar to that described here was used recently in an E, coli 
study (28) and revealed point mutations for all MEP path­
way genes except ispH.
The system described here for Salmonella bacteria employs 
a strain with genes of the MVA pathway of yeast inserted in 
the bacterial gene dxs, which encodes deoxyxylulose phos­
phate synthase in the bacterial MEP pathway. This strain uses 
the MEP pathway when supplied with methylerythritol and the 
MVA pathway when supplied with MVA. Extensive attempts 
to isolate insertion mutations in the MEP pathway of Salmo­
nella bacteria by this means were unsuccessful. However, fol­
lowing mutagenesis with diethyl sulfate (DES), mutants were 
recovered for all steps in the MEP pathway downstream of dxr 
that were identified by alternative biochemical or bioinfor­
matic methods. Mutants with mutations in the srl operon, 
which has been implicated in the uptake and phosphorylation 
of exogenously supplied ME, were also recovered.
The failure of the genetic approach using transposons was 
surprising, since constructed Salmonella mutations for each of 
the genes showed the expected phenotype when introduced 
into the parental strain—an absolute requirement for meval­
onate (33). The evidence described here demonstrates the 
efficacy of the genetic system and raises the question of why 
transposon mutagenesis failed. This genetic system promises to 
be a useful adjunct to other methods in further analysis of the 
bacterial MEP pathway, which remains an attractive target 
for the design of antibiotic, antimalarial, and herbicidal com­
pounds, as demonstrated by the use of fosmidomycin, a MEP 
pathway inhibitor used in treatment of bacterial infections 
and malaria (13).
Structural information about the active sites of the MEP 
pathway proteins can be an invaluable tool for the rational 
design of inhibitors. While the crystal structures have been 
reported for the proteins encoded by dxr (21,39), ispD (13, 23), 

















TABLE 1. Salmonella enterica scrovar Typhimurium I.T2 strains 
used in this study
Strain Description Reference and/ or source
RMC26 I,T2 dxs(swap)::MVA,)pcn This work, 28
CR4 RMC26 /.vpD(swap)::CAT This work, 28
CR33 RMC26 up£(swap)::CAT This work
CR34 RMC26 /.vpG'(swap)::CAT This work
CR35 RMC26 upif(swap)::CAT This work
CR5 RMC26 ,sr/£(swap)::CAT This work
DM269 f/)i/::Tni0d-tct 32
available for the other MEP pathway proteins. In addition, the 
oxygen sensitivity of the iron sulfur proteins encoded by ispG 
and ispH (30, 38) presents special problems when work is 
performed with the purified enzymes. In such cases, alternative 
methods, such as random mutagenesis, are useful for identify­
ing residues in the enzymes essential for function and a method 
for testing the in vivo efficacy of potential inhibitors.
MATERIALS AND METHODS
Genetic media and methods. Chloramphenicol (Cam), kanamycin (Kan), tet­
racycline (Tet), L-arahinose (i.-ara), mevalonolactone, and DES were purchased 
from Sigma. Klentaq-LA polymerase was purchased from Clontech. Luria-Ber- 
tani (LB) full medium was used with or without supplementation for all growth 
conditions (27). E minimal medium was prepared without carbon as described by 
Vogel and Bonner (35). Cam was used at a final concentration of 20 jxg/ml, Kan 
at 40 |xg/ml, and Tet at 30 jxg/ml unless otherwise noted. Methylerythritol was 
synthesized using the method of Duvold (8) and supplemented at a final con­
centration of 50 jxg/ml. i.-Arabinose was used at a final concentration of 0.02%. 
Mevalonic acid was prepared by hydrolysis of 1 volume of 1 M mevalonolactone 
with 1.02 volumes of 1 M KOH, followed by incubation at 37°C for 30 min, and 
used at a final concentration of 5 mM.
Transductions were mediated by the high-frequency P22 mutant HT10511 
ini-201 as previously described (29). Phage P22 lysates were prepared as 
previously described (7). All DNA sequencing was performed at the Health 
Sciences Center Sequencing Facility, Eccles Institute of Human Genetics, 
University of Utah.
Cloning and sequencing methods. Genomic DNA was isolated using Easy 
DNA kits (Invitrogen). PCR was performed using a Perkin-Elmer GeneAmp 
PCR system 2400 DNA thermal cycler as directed by the polymerase vendor. 
PCR nucleotide mix was purchased from Roche Molecular Biochemicals. All 
oligonucleotides were synthesized by the Protein/DNA Core Facility of the Utah 
Regional Cancer Center. Agarose gel purifications and PCR purifications of 
DNA were performed using QIAquick gel extraction kits and PCR purification 
kits (QIAGEN), respectively. Sequence searches were performed on the Na­
tional Center for Biotechnology Information (NCBI) and Washington University 
School of Medicine Genome Sequencing Center BLAST servers. Gene se­
quences were downloaded from NCBI. Sequence alignments were performed 
using Vector NU Align-X software. Strains used in this work are listed in Table 1, 
and oligonucleotides are described in Table 2.
Identifying and classifying mutations. Mutants were generated by exposing 
stationary-phase cultures of RMC26 to a saturated solution of DES in E me­
dium. A saturated DES solution was prepared by placing two drops of DES in 5 
ml of E medium. The solution was mixed and incubated at 37° for 10 min. To the 
saturated DES solution, 0.1 ml of RMC26 stationary-phase culture was added. 
After the cells were incubated at 37° for 30 min, 0.1 ml aliquots were used to 
inoculate 5 ml overnight cultures of LB-MVA-L-ara-Kan medium. The follow­
ing day, full-cell suspensions were diluted 106-fold, and 0.1 ml of diluted cells 
was plated to LB-MVA-L-ara-Kan plates. A separate overnight culture was 
used for each plate in an effort to reduce the isolation of sibling mutants. 
After 2 days growth at 37°C, colonies were replica printed to LB-MVA-L- 
ara-Kan and LB-ME-Kan media. Mutants were isolated that demonstrated 
viability in the presence of MVA-L-ara but not in the presence of ME. 
Mutants were verified by patching to media supplemented with MVA-L-ara 
and printing to both MVA-L-ara media and ME-L-ara media.
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sSEQsrlAEB2............................. GCTGGTAGGT CTGGTG ACG A
sSEQsrlAEB3............................. CCAGCCTGCCAAAACGACAT
sSEQsrlAEB4............................. TCGGCGTACCTTCTGTGCTG
Identification of isolated mutants. Strains CR5, CR33, CR34, and CR35 (see 
Table 1) were constructed from parental strain RMC26 to contain a chloram­
phenicol acetyltransferase (CAT) cassette in place of individual MEP pathway 
genes or srlE by using linear recombination as previously described (33). Isolated 
mutants were used as recipients in P22-mediated transductional crosses with 
donor strains having known MEP genes or genes within the srl operon replaced 
by a CAT cassette. The following strains, all with the MVA operon inserted in 
the chromosomal copy of dxs, were used as donors in the P22 crosses: CR4 for 
the ispD replacement, CR33 for the ispE replacement, CR34 for the ispG re­
placement, CR35 for the ispH replacement, and CR5 for the srlE replacement. 
RMC26 was also used as a donor in a control cross. DES-generated random 
mutants were used as recipients in the transductional crosses and were plated to 
LB-ME-Kan media. The number of transductants from each cross was counted. 
Any recipient point mutant that could not generate recombinants able to use 
2-C-methyl-D-erythritol (ME) when crossed with a particular donor mutant was 
likely to have a mutation in the same gene that was lacking in the donor strain.
Once identified by cross, the mutant allele was PCR amplified from the 
genomic template by use of KlenTa^ LA polymerase mix, followed by se­
quencing of the amplificate to identify the position of mutation. In cases 
where the results of complementation by strains with disruptions in MEP 
pathway genes were ambiguous, the implicated genes were amplified and 
sequenced. PCRs were performed in duplicate, followed by sequencing in 
duplicate. Primers used to amplify the target genes were as follows: for ispD 
and ispF, primers sAMPygbPB and asAMPygbPB; for ispE, primers sAMPy 
chB and asAMPychB; for ispG, primers sAMPgcpE and asAMPgcpE; for ispH, 
primers sAMPlytB and asAMPlytB; and for srlA, srlB, and srlE, primers sAMPsr 
1AEB and asAMPsrlAEB. Hie following sequencing primers were used for each 
target gene: primers sSEQygbPBl, sSEQygbPB2, and sSEQyghPB3 were used to 
sequence ispD and ispF amplificates; primers sSEQychBl and sSEQychB2 were 
used for ispE amplificates; primers sSEQgcpE and asSEQgcpE were used for 
ispG; sSEQlytBl and sSEQlytB2 were used for ispH; and sSEQsrlAEBl- 
sSEQsrlAEB4 were used for srl A, srlE, and srlB.
A subset of mutant strains that failed to grow on ME as an isoprenoid 
precursor did not appear to have mutations in any known MEP pathway gene, as 
determined by the recombination test described above. To test their dependence 
on the MVA operon, these mutants were used as recipients in transductional 
crosses with donor DM269 (37), which harbors a TnI0d-Tet insertion in the 
chromosomal copy of thil, a thiamine biosynthesis gene in close proximity to dxs. 
As a control, RMC26, CR4, and CR5 were also used as recipients in the same 
cross. Recombinants were selected on LB-MVA-L-ara-Tet media. After 2 days 
growth at 37°C, transductants were replica printed to LB-MVA-L-ara-Kan me­
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ispD ispfc ispFu ispG ispH sr!A l> s il l.  None
FIG. 1. Identification of DES-gcncratcd mutations by complemen­
tation. A) Bracketed region suggests the presence of a 44-kb recom­
bination fragment. A donor chromosome with a mutation in a MEP 
pathway gene, different (isp l) than the unidentified mutants (isp l), 
produces a recombination fragment able to repair the unidentified 
mutation. B) A donor chromosome with a mutation in the same gene 
as the recipient chromosome does not produce a recombination frag­
ment able to repair the lethal mutation.
RESULTS
Structure of the parental stain RMC26. Strain RMC26 has 
a synthetic opcron encoding the Saccharomyces cerevisiae 
genes ERG 12, ERGS, and ERG19 (for the'conversion of 
MVA to IPP) inserted into the chromosomal copy of cLxs and 
expressed from an arabinose-inducible promoter (1). This 
strain has an absolute growth requirement for an early com­
pound of either the yeast MVA pathway or for the bacterial 
MEP pathway. When either 1-deoxy-n-xylulose or ME is sup­
plied, the bacterial pathway is used. When MVA and the in­
ducer i-ara arc provided, the yeast pathway is used. Mutants 
with disruptions in the MEP pathway were identified by their 
viability on media supplemented with MVA-i -ara but not on 
medium with ME.
Isolating mutants in strain RMC26. Random mutants were 
generated in Salmonella serovar Typhimurium strain RMC26 
by exposure to DES, a DNA-alkylating agent that results in 
primarily G:C to A:T transitions (12). Approximately 20,000 
colonics were screened for mutations that allow growth in the 
presence of M VA-L-ara but not in the presence of ME. A total 
of 28 mutants were isolated that grew less well on media 
containing ME than on media supplemented with M VA-L-ara. 
Of the total, 23 exhibited a complete lack of growth on ME and 
were further characterized. The remaining five mutants showed 
only slightly impaired growth on ME, suggestive of partial loss of 
functions, and were not pursued.
Characterization of mutations. To identify the mutated 
genes, cach of the mutants was used as recipient in a trans­
duction cross with individual donor strains bearing CAT re­
placements in one of the known MEP pathway genes down­
stream of dxr and srlE (Fig. I). Selection was made for ability 
to grow on ME. A failure to yield recombinants indicated that 
the recipient point mutation affected the gene that was deleted 
in the donor. The implicated region of the mutant chromo­
some was amplified from genomic DNA using KlenTaq LA 
























“ Complementation deficiency mapped with deletion insertion in ispl). 
h Complementation deficiency mapped with deletion insertion in srlE. 
c Mutations noted are amino acid substitutions. Numbering is consistent with 
the enzymes from S. typhimurium. unk, not identified; Stp, stop codons.
Each mutant allele was PCR amplified and sequenced in du­
plicate to reduce the chance of reporting a mutation intro­
duced by PCR or an error in sequencing. This possibility was 
further reduced by using IQcnTaq LA polymerase mix (3), 
which contains a small amount of editing 3' exonuclcase which 
provides proofreading and reduces the probability of introduc­
ing mutations by PCR.
All of the sequenced mutations were G:C-to-A:T transitions, 
as cxpcctcd by the use of the ethylating agent DES (12). Of the 
23 mutants characterized, four independent mutations were 
found in ispD, one in ispE, two in ispF, four in ispG, one in 
ispH, and six in the srl opcron (Table 3). The remaining six 
mutants were recombinationally repaired in crosses with any of 
the donor strains lacking one of the known genes in the MEP 
pathway, suggesting that their failure to grow on ME was not 
due to lack of a known MEP enzyme.
If these strains carried some novel block in the MEP path­
way, they would be cxpcctcd to require their MVA opcron to 
supply isoprenoids. To test this, the MVA opcron was removed 
from cach mutant by a cross with donor strain DM269 (37), 
which carries a TnlO insertion near the cLxs gene in which the 
MVA opcron was inserted. In all six cases, more than 90% of 
Tetr transductants lost the MVA opcron (and became dsx+), as 
determined by their Kan sensitivity. This is the same loss fre­
quency observed in crosses between donor DM269 and recip­
ient RMC26, with no additional blocks in the MEP pathway, 
and recipient CR5, which has the insertion of a CAT cassette 
in the chromosomal copy of srlE. These dsx+ transductants 
grew normally with without added MVA or MEP, demonstrat­
ing that their de novo MEP pathway is unaffected by any of the 
six unlinked mutations. When this cross was done using a 
recipient with a block in MEP (e.g., CR4 which has a CAT 
insertion in the chromosomal copy of ispD), none of the trans­
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essential when the endogenous MEP pathway is blocked. We 
conclude that these six mutants have an intact MEP pathway 
and failed to grow on ME in the original background because 
they interfere with assimilation of ME (outside the normal 
MEP pathway).
DISCUSSION
A system is described for isolation of mutants with blocks in 
the MEP pathway of S. typhimurium. Using this screen, ap­
proximately 20,000 DES-mutagenized colonies were tested, 
and 23 mutants were isolated that exhibited a strong growth 
defect on media containing ME compared to the results seen 
with media containing MVA-i,-ara. The gene affected by each 
of the 23 mutations was identified by failure to recombine with 
deletions of one of the known genes in the MEP pathway, and 
their base changes were determined by DNA sequencing. The 
resulting mutations included blocks in each of the genes of the 
MEP pathway downstream of dxr. In the study of E. coli re­
ported by Sauret-Gueto et al. (28), a screen of —27,000 strains 
yielded no mutations in ispH, when the expected frequency of 
hits was —2.7. Those authors suggested that the region of the
E. coli chromosome might be poorly accessible to the mutagen. 
This now appears unlikely, and the absence of an ispH mutant 
more likely reflects the small number of mutations isolated. In 
addition, we isolated several strains bearing mutations in the 
sorbitol operon, in agreement with previous work suggesting its 
involvement in the import and phosphorylation of exogenous 
ME (33).
The results reported here for a chemical mutagen contrast 
with extensive earlier mutant screens looking for insertional 
inactivation of MEP pathway genes. These hunts employed a 
MutJ(Cm) element, a derivative of phage Mu carrying chlor­
amphenicol resistance (6). No insertion mutations were found 
in any gene of the MEP pathway. The only genes detected by 
insertions were in the sorbitol phosphotransferase system 
(PTS) (33). Sufficient insertion mutations (150,000) were 
screened to assure complete coverage—on the order of 30 hits 
per gene. At this point we have no explanation for this dis­
crepancy but suggest several possibilities below.
The puzzle posed by failure to identify insertion mutations 
might reflect any of the following possibilities, (i) The isp genes 
could be poor targets for the insertion element used. This 
seems unlikely, since this transposon has been used extensively 
in other systems and shows very little target specificity. While 
rare genes might be poor targets, it seems unlikely that all of 
the scattered genes for one particular pathway would be poor 
targets, (ii) The chloramphenicol resistance might be unex­
pressed in strains using the MVA instead of the MEP pathway, 
or chloramphenicol might interfere with functioning of the 
MVA pathway. This seems unlikely, since successfully con­
structed MEP mutants carried a Cam1' gene very similar to that 
cloned into the various MEP genes and all these mutants 
showed simultaneous resistance to chloramphenicol and ability 
to use MVA. (iii) Intermediates in the MEP or MVA pathways 
might affect transposition. We have shown that transposition 
occurs in cells of the parent strain grown on mevalonate both 
with and without added methylerythritol. Thus, no intermedi­
ate in the MVA pathway interferes with transposition and no 
intermediate in the MEP pathway is required for transposition.
Any methylerythritol phosphate accumulated in the parent 
(dxs) strain does not inhibit transposition. The idea that a 
particular internal MEP intermediate inhibits transposition 
does not explain the results, since the mutational block would 
not be imposed until after transposition had occurred and 
methylerythritol was provided, (iv) The explanation we favor is 
that polar insertions in the MEP genes are nonviable. While it 
seems unlikely that essential genes are located downstream of 
each MEP gene, this possibility fits our data quite well, based 
on the evidence summarized below.
The insertion element used is strongly polar, and such po­
larity has been shown to be sufficient to eliminate expression of 
downstream genes in other systems. The constructed MEP 
pathway mutants received a Cam1' cassette that is known to 
have outward-directed promoters at both sides and would thus 
provide for expression of downstream genes. The idea of lethal 
polar effects is consistent with the rarity of nonsense mutations 
among the recovered MEP point mutations; such mutations 
would be expected to show polarity and may also be counters­
elected. The general idea predicts that all isoprenoid biosyn­
thetic genes are in multigene operons with essential distal 
genes. This prediction has not yet been tested, but such mixed- 
function operons are known (17, 19, 34).
Of the genes downstream of dxr in the MEP pathway, 
crystal structures are reported for the proteins encoded by 
ispD (14, 22), ispE (20, 36), and ispF (13, 23, 31). Four 
mutants, defective in ispD , were isolated. PM 18 had a non­
sense mutation (Q100). The remaining three had missense 
mutations in PM11 (E196K), PM17 (G130E), and PM23 
(G92Q). The crystal structure of E. coli 4-diphosphocytidyl-2- 
C-methyl-n-erythritol (CDP-ME) synthase, encoded by ispD, 
suggests that the protein is a homodimer (22). Each subunit is 
comprised of two structurally distinct domains, a larger core 
domain, comprised of residues 1 to 136 and 160 to 236, and a 
smaller lobe domain, comprised of residues 137 to 159. The 
core domain is globular in structure and includes a distinctive 
parallel p-sheet motif. The lobe domains of the two subunits 
resemble "curved arms" which interlock to mediate dimer for­
mation and organize parts of the catalytic site (22). The trun­
cated IspD protein resulting from the nonsense mutation in 
PM 18 lacks both the small lobe domain and a portion of the 
large globular domain, making dimer formation and catalysis 
unlikely. The three missense mutations do not appear in amino 
acids thought to be involved directly in substrate binding or 
catalysis as predicted by the crystal structure. In addition, none 
of the three mutated residues are strictly conserved, as deter­
mined on the basis of sequence alignments of the proteins 
from 35 organisms. Flowever, in all three cases a change in 
polarity of the residue occurs that may translate into altered 
protein structure. Negatively charged Glul96 is changed to 
positively charged lysine, while nonpolar Gly92 and Glyl30 are 
mutated to larger polar glutamine and negatively charged glu­
tamate, respectively. Aside from polarity, the protein structure 
may be compromised by steric interactions in which small 
buried glycine residues are replaced by the much larger glu­
tamine and glutamate residues.
A single missense mutation was isolated in ispE (G239R). 
This same mutation was isolated by Sauret-Gueto and cowork­
ers (28) in ethyl methanesulfonate-generated E. coli mutants 
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motif characterized by the consensus sequence G-[S,T]-G that 
is critical for enzyme function. The crystal structure of the IspE 
protein from E. coli implicates Gly239 as an important residue 
in substrate binding. The Gly239 amide is thought to aid in 
positioning Asnl2 through hydrogen bonding interactions, 
which allow the residue to in turn hydrogen bond with the 04  
hydroxyl group in CDP-ME (20). The substitution of the much 
larger and charged Arg residue may disrupt the secondary 
structure of the protein backbone sufficiently to inhibit forma­
tion of the stabilizing hydrogen bond between the amide and 
AsnI2, which in turn likely disrupts substrate binding.
Two missense mutations were isolated in the protein en­
coded by ispF. The crystal structures of E. coli 2-C-mcthyl-o- 
erythritol-2,4-cyclodiphosphate synthase show that the protein 
is a bell-shaped homotrimer (13, 23, 31). Each monomer is 
comprised of a large and a small p-sheet and four a-helices. 
The catalytic sites are located at the interfaces of each of the 
three subunits and are characterized by three distinct binding 
pockets: a central pocket binds the sugar and diphosphate of 
the cytidyl moiety; a second pocket binds the nucleoside; and a 
third pocket binds the 2-phosphate and carbon chain of the 
2C-methyl-i>erythritol moiety (31). Both mutations, A33V and 
D38N, appear to be very near residues involved in substrate 
binding by the third pocket. The hydrophilic side chains of 
Ser35, Ser73, and Asp63 are thought to be important for bind­
ing and positioning the 2C-methyl-i>erythritol moiety (31). 
Additionally, His34 is thought to stabilize a flexible loop which 
caps the active site (31). The pentapeptide sequence starting at 
His34, including fully conserved residues Ser35 and Asp38, is 
highly conserved and is positioned along the side of the active 
site, suggesting a role in substrate binding (13). Though Asp38 
is not directly implicated in substrate binding or catalysis by the 
current crystal structures, its involvement in enzyme activity is 
not surprising given the close proximity to the binding site and 
fully conserved nature of the residue. Similarly, the close prox­
imity of Ala33 may suggest that it is important for correct 
positioning of the conserved pentapeptide within the active 
site.
Though crystal structure data are not available for the re­
maining enzymes of the MEP pathway, some structural infor­
mation can be inferred based on function and homology to 
enzymes with better characterized motifs. The amino acid se­
quence of the IspG protein has strong homology to enzymes 
possessing a [4Fe-4S] cluster (30), and a conserved ferrodoxin 
motif spanning residues 300 to 319 in E. coli has been identi­
fied (38). However, alignments have failed to identify addi­
tional conserved motifs that would give an insight into the 
mechanism of catalysis (2, 4). IspG possesses three fully con­
served cysteines, residues 269, 272, and 305 in the S. typhi­
murium enzyme, which have been suggested to participate in 
iron binding (10). The current screen identified four missense 
mutations in ispG: R237C (PM3), RI33H (PM5), G309R 
(PM 19), and G206R (PM25). Of these, only G309R is not in 
a fully conserved residue. However, Gly309 is highly con­
served, located within the ferrodoxin motif and near a con­
served Cys305. The other three residues, Arg 133, Arg237, and 
Gly206, are fully conserved among bacteria, plants, and the 
malaria parasite Plasmodium falciparum. The polar-charged 
nature of Arg 133 and Arg237 allows the possibility of in­
volvement in substrate binding or catalysis, while the small
size and nonpolar aliphatic nature of Gly206 would suggest 
a structural role. Nonetheless, identification of these resi­
dues by the current screen confirms that they are essential 
for enzyme function.
A single missense mutation in ispH was isolated. Like IspG, 
IspH is a [4Fe-4S] protein and possesses three fully conserved 
cysteine residues at positions 12, 96, and 197 in Salmonella 
serovar Typhimurium. It has been suggested that these cys­
teines are involved in iron binding (2). Therefore, it is not 
surprising that the missense mutation isolated in ispH (C96Y) 
results in a loss of function phenotype, which may be attributed 
to the inability of the protein to form the [4Fe-4S] cluster.
Five DES-generated mutants, showing MVA auxotrophy, 
were isolated in the sorbitol operon, which was previously 
implicated in the import and phosphorylation of exogenous 
ME (33). While these mutations are not directly relevant to the 
function of the MEP pathway, isolation of these mutations 
supports the current model in which exogenous ME is im­
ported and phosphorylated by the sorbitol phosphoenolpyruvate: 
phosphotransferase system. While use of an insertion element 
to generate gene disruptions in previous screens for MVA 
auxotrophic mutants resulted in the isolation of only srlE, the 
current screen also identified a random mutation in srlA. Both 
srlA and srlB had been previously implicated in import and 
phosphorylation by directed disruption (28). A single mutant, 
PMI5, carried two independent mutations, a missense muta­
tion in srlA (G20Q) and a nonsense mutation in srlE (W3 I5), 
as determined by sequencing. It is unclear at this time which 
mutation results in the MVA-dependent phenotype. One ad­
ditional nonsense mutation was isolated in srlA at WLI. Thus, 
inactivation of the SrlA protein is not surprising given the early 
translation termination. Three additional point mutations were 
isolated in srlE, G78A, G28IA, and G295A. The substitution 
of glycine to alanine is conservative. However, two of these 
glycines, G78 and G295, are fully conserved among sorbitol 
PTSs, which may explain the loss of function for the similar 
substitution. It is unclear why G28 IA causes a loss-of-function 
phenotype. Although glycine 281 is highly conserved, alanine 
substitutes for glycine at that position in S. mu tans.
Six mutants isolated in the screen failed to use ME but were 
not completely characterized, because they do not affect func­
tion of the MEP pathway. All six were used as recipients in a 
transductional cross with donor DM269, which has a TnlO  
insertion in the th il gene closely linked to the clxs insertion 
(containing MVA pathway genes) in the parent strain. Many 
Tetr recombinants lost the clxs insertion and the MVA genes 
and regained a functional clxs gene. These transductants still 
carried the new mutation but were clearly able to use the 
bacterial MEP pathway. All of the six mutants thus failed to 
grow on ME in the parent clxs background due to some defect 
in uptake or phosphorylation of methylerythritol. They have no 
impairment in the MEP pathway. The behavior of these Dxs+ 
transductants contrasts with that for the same recombinants 
obtained using recipient strain CR4, which bears a dysfunc­
tional copy of the MEP pathway gene ispD. We suggest (but 
have not directly tested) that these six mutations affect the 
sorbitol PTS, which requires proteins in addition to SrlA, SrlE, 
and SrlB. The six mutations could thus block uptake of ME 
without blocking the MEP pathway or affecting the srl operon. 
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identified in this screen or that described by Sauret-Giieto 
(28). This agrees with biochemical and bioinformatic studies 
indicating that all genes required for biosynthesis of IPP and 
DMAPP by MEP pathway have been identified. Both IspG 
(GcpE) and IspH (LytB) enzymes require regeneration systems 
such as flavodoxin, flavodoxin reductase, and NADPH for activity 
in vitro (30). Regeneration systems specific to the [4Fe-4S] pro­
teins, IspG and IspH, have been hypothesized to exist in vivo, but 
this has not been conclusively established. Genes encoding en­
zymes for the specific reduction of either IspG or IspH are un­
likely to exist. Similarly, screens performed with E. coli failed to 
isolate strains with mutations in additional genes (28).
Six of the mutants recovered that failed to grow on ME were 
shown to possess an intact MEP pathway. We suggest that 
these mutants are likely to interfere with some early step in 
uptake and metabolism of ME or to make strains sensitive to 
growth inhibition by ME.
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